Adam Feuerstein
Senior Writer, Biotech at STAT
Reporter @statnews. The Harry Kane of biotech. Dog ❤️er. Polk Award winner. #COYS. Said one analyst: The likes of Adam Feuerstein attack viciously.
Articles
-
1 week ago |
statnews.com | Allison DeAngelis |Adam Feuerstein |Elaine Chen
Is there more funding coming for the biotech industry? Will the pharmaceutical industry be hit with tariffs? And is it possible to reason with RFK Jr.? We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. John Crowley, the CEO of industry lobbying group BIO, joins us to discuss the layoffs at the Food and Drug Administration, RFK Jr.’s comments on Novavax’s Covid-19 vaccine, and how the trade group is communicating with the Trump administration.
-
2 weeks ago |
statnews.com | Adam Feuerstein
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. “Always you, with the bad news.” — King Henry VIII to Thomas Cromwell. Biotech stocks and the broader markets snapped higher Wednesday after President Trump announced a 90-day pause on reciprocal tariffs for all countries except China, backing down from a trade policy that had triggered a global macroeconomic crisis.
-
2 weeks ago |
statnews.com | Adam Feuerstein |Elaine Chen |Allison DeAngelis
Turmoil, job cuts and forced ousters of high-ranking officials at federal health agencies. Marty Makary’s rough first week as FDA Commissioner. Biotech stocks tumble even further. President Trump’s “Liberation Day” tariffs roil global markets. We talk about biotech’s volatile week, plus interview AstraZeneca R&D executive Sharon Barr, on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast.
-
3 weeks ago |
statnews.com | Adam Feuerstein
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. A warm welcome to all my new subscribers who joined after our very successful email pitch. I love that you’re here — and thank you!Do you have a friend or colleague who might enjoy a STAT subscription and this newsletter? Feel free to forward it to them, and they can use this discount offer, too.
-
3 weeks ago |
statnews.com | Adam Feuerstein
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter. New this quarter, we’re tracking a select number of Food and Drug Administration-drug sponsor meetings as a potential signal that agency operations are being impacted by changes made by the Trump administration. Vera Therapeutics: Top-line results from the atacicept Phase 3 ORIGIN trial in IgA nephropathy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 116K
- Tweets
- 80K
- DMs Open
- Yes
X friends - I’m off until April 21. I hope for a reprieve from this macro mess and an $XBI recovery by the time I return. May all your smid bios be acquired while I’m gone. Keep breathing.
“This is another example of Kennedy being an ignoramus about vaccination, if not other things as well. And you can quote me on that,” said Stanley Plotkin, a co-developer of the rotavirus vaccine and of the vaccine that protects against rubella. Plotkin is a professor emeritus at
Health secretary RFK Jr. declares certain vaccines have ‘never worked,’ flummoxing scientists https://t.co/ENCfkGGivj via @HelenBranswell
BIO’s John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding https://t.co/CPVNpmaB3n via @statnews
